Intra-Cellular Therapies Stock Forecast
Recent Intra-Cellular Therapies Stock Price |
|
Intra-Cellular Therapies Stock Forecast Price |
$70.34 |
+29.27% |
$90.93 |
As of 2024-05-03
Recent Intra-Cellular Therapies Analyst Ratings Breakdown |
|
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
Strong buy ratings: |
11 |
11 |
11 |
11 |
Buy ratings: |
2 |
2 |
2 |
2 |
Hold ratings: |
2 |
2 |
2 |
2 |
Sell ratings: |
0 |
0 |
0 |
0 |
Strong sell ratings: |
0 |
0 |
0 |
0 |
Average rating: |
1.4 |
1.4 |
1.4 |
1.4 |
In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell.
The presented Intra-Cellular Therapies stock forecast (traded under symbol ITCI), for forward-twelve-months price target as shown at the top of this page, gives you the average Intra-Cellular Therapies stock forecast for forward target price for symbol ITCI, across the 15 analysts covering Intra-Cellular Therapies (ITCI), as reported in
data provided by Zacks Investment Research via Quandl.com.
Investors should also take note that the median Intra-Cellular Therapies stock forecast price target (i.e. representing the middle ground number where half of analysts had a higher Intra-Cellular Therapies stock forecast and half had a lower Intra-Cellular Therapies stock forecast) was $90.0 as of 2024-05-03 (which is a different mathematical metric versus taking the average or mean), while the
highest Intra-Cellular Therapies stock forecast in the analyst group was $120.0, and the lowest Intra-Cellular Therapies stock forecast in the analyst group was
$65.0, with a standard deviation of $13.976. Get the latest Zacks research report on ITCI — FREE
Top Analyst Picks of the Dow
The Top 20 Largest U.S. Stocks By Market Cap
|
May 3, 2024 1:59 PM Eastern
Strong Buy (3.60 out of 4)
62nd percentile
|
|